During the forecast period 2023-2033, the Chronic Granulomatous Disease (CGD) Management Market is expected to grow at a value of 4.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Chronic Granulomatous disease (CGD) management is expected to rise up to a market valuation of US$ 2.11 Billion.
It is anticipated that the market will experience growth owing to various reasons such as the growing incidence of uncommon diseases, greater healthcare expenditure in developed countries, and heightened research and development endeavors.
The market growth for chronic granulomatous disease treatment is also expected to be spurred by shifts in lifestyle and dietary changes within the forecast period. Moreover, consistent efforts in research and development by key companies to innovate medication for the treatment of CBD is expected to boot the overall market growth.
Download Sample Copy: https://www.futuremarketinsights.com/reports/sample/rep-gb-16435
Furthermore, North America and Europe are two major regions contributing to the growth of the CGD management market. This is owing to the developed healthcare infrastructure and presence of key players in the region. Furthermore, the progression of technology and increased government funding for the healthcare industry are expected to provide ample opportunities for the expansion of the market for treatment of chronic granulomatous disease in the foreseeable future
Key Takeaways from the Market Study
- By type, Trimethoprim is expected to possess 40% market share for CGD market in 2023.
- By end user, Hospitals are expected to hold 40% of the market share in 2023 for Chronic Granulomatous disease (CGD) management market.
- North America is expected to possess 45% market share for Chronic Granulomatous disease (CGD) management market in 2023.
- Europe Chronic Granulomatous disease (CGD) management market size is expected to possess 35% market share in 2023.
“Increase in research activities along with prevalence of rare diseases is a key driver for the CGD management market.” states an FMI analyst
Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-16435
Competitive Landscape
- In July 2018, Clinigen Group plc acquired the global rights to Imukin from Horizon Pharma. The company is focusing on reduce the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD)
- In January 2020, Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
Key Companies Profiled:
- Clinigen Group plc
- Orchard Therapeutics plc2032
- Horizon Therapeutics plc
- ViroMed. Co. Ltd
- Bellicum Pharmaceuticals, Inc
- Pfizer Inc
- Hoffmann-La Roche Ltd
- Novartis AG
- Lonza
- GlaxoSmithKline plc
- Eli Lilly and Company
- Johnson & Johnson Services, Inc
- Merck KGaA
Use promo code ->> FMITODAY to get a flat 20% discount
Key Segments Profiled in the Chronic Granulomatous Disease (CGD) Management Industry Survey
Type:
- X-Linked Chronic Granulomatous Disease
- Autosomal Recessive Chronic Granulomatous Disease
Diagnosis:
- Neutrophil Function Tests
- Genetic Testing
- Prenatal Testing
Treatment:
- Infection Management
- Trimethoprim
- Sulfamethoxazole
- Itraconazole
- Interferon-gamma
- Stem Cell Transplantation
- Others
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
